Pliant's BEACON-IPF trial terminated after DSMB recommendation; results posted
Pliant Therapeutics' Phase 2 bexotegrast study in idiopathic pulmonary fibrosis ended early on a safety monitoring board's recommendation, with results posted August 5, 2026.
The week's main item concerns a halted Phase 2 IPF study from Pliant Therapeutics.
- BEACON-IPF, a Phase 2 study of bexotegrast (PLN-74809) in idiopathic pulmonary fibrosis, is listed as terminated, with the stated reason being a DSMB recommendation1. The trial had tested two doses of bexotegrast, 160 and 320 mg, taken for 52 weeks by participants with IPF taking and not taking background therapy such as nintedanib or pirfenidone1, with 320 participants actually enrolled1 and the primary outcome measuring change from baseline in forced vital capacity, the total amount of air exhaled during a spirometer-based lung function test, at Week 521. Results were first posted on 2026-08-051.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.